Form 4: Incyte Director Katherine High Receives Significant Equity Awards

Incyte Corporation Director Katherine A. High was granted 2,518 restricted stock units and 9,216 non-qualified stock options as part of her compensation, aligning her interests with shareholder value.

Summary

• Incyte Corporation Director Katherine A. High was granted 2,518 shares of common stock in the form of restricted stock units (RSUs) on June 10, 2025, with a transaction price of $0.
• Additionally, Ms. High received 9,216 non-qualified stock options on June 10, 2025, with an exercise price of $70.07 per share and a transaction price of $0 for the option itself.
• Following these transactions, Ms. High beneficially owns 13,341 shares of common stock, which includes the newly granted 2,518 unvested RSUs.
• She also beneficially owns 9,216 non-qualified stock options.
• The RSUs and stock options are scheduled to vest in full on the first anniversary of the grant date (June 10, 2026), or earlier upon the date of the next regular annual meeting of the Company's stockholders or a change of control.
• The RSUs may be settled only for shares of common stock on a one-for-one basis.
• The filing was made on June 12, 2025, by Elizabeth Feeney, Attorney-In-Fact for Katherine A. High.

Sentiment

Score: 7

Explanation: The sentiment is positive as it indicates routine and expected compensation for a director, aligning their interests with the company's performance. It does not reflect on the company's operational or financial performance directly, but rather on its governance and compensation practices.

Positives

• The grant of restricted stock units and stock options to Director Katherine A. High aligns her financial interests directly with the long-term performance and shareholder value of Incyte Corporation.
• Equity-based compensation is a standard practice for retaining and incentivizing key directors and management, promoting commitment to company growth.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic outlook, as it pertains solely to an insider's equity compensation.

Industry Context

The granting of equity awards, such as restricted stock units and stock options, to directors is a common practice across the biotechnology and pharmaceutical industries. This compensation structure is widely used to align the interests of board members with those of shareholders, encouraging long-term value creation and retention of experienced leadership.

Comparison to Industry Standards

• The structure of equity compensation, including RSUs and stock options with vesting periods tied to service or specific events (like change of control), is consistent with compensation practices observed in comparable biopharmaceutical companies such as Gilead Sciences, Amgen, and Regeneron Pharmaceuticals.
• The exercise price of $70.07 for the options reflects the market price at the time of grant, which is standard for non-qualified stock options.
• The vesting schedule (one year from grant or earlier upon annual meeting/change of control) is a typical short-to-medium term incentive structure for director equity awards in the sector.

Stakeholder Impact

• Shareholders: The equity awards align the director's interests with shareholder value, potentially leading to decisions that benefit long-term stock performance.
• Employees: No direct impact on general employees from this specific filing, though it reflects the company's overall compensation philosophy for leadership.

Next Steps

• The restricted stock units and stock options granted to Katherine A. High are expected to vest on June 10, 2026, or earlier under specified conditions (next annual meeting or change of control).

Key Dates

Keywords

Incyte Corporation, INCY, Form 4, Insider Transaction, Equity Award, Restricted Stock Units, RSU, Stock Option, Director Compensation, Beneficial Ownership